文献速递白血病

p53单倍剂量不足或缺失在FLT3-ITD突变急性髓系白血病发生中的独特作用

A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.
PubMed 文献 · Leukemia · 2021-11-03

在急性髓系白血病中p53蛋白缺失或减少约50%,比TP53突变更常见;FLT3-ITD突变AML预后不良且与野生型p53功能障碍高度相关。本研究构建FLT3-ITD敲入;p53敲除双转基因小鼠,发现两种改变强烈协同诱导细胞遗传学正常的AML,且白血病细胞对蛋白酶体抑制剂卡非佐米高度敏感。

要点

  • p53单倍剂量不足或缺失与FLT3-ITD协同诱导细胞遗传学正常的AML
  • Htra3上调与Lin28a下调共同促进增殖并抑制凋亡和分化
  • 双转基因小鼠白血病细胞对卡非佐米高度敏感,卡非佐米增强靶向AXL的活性

核心结论

  • p53单倍剂量不足或缺失在FLT3-ITD突变AML发生中具有独特作用。

研究设计与样本

  • 研究构建了FLT3-ITD敲入;p53敲除(杂合和纯合)双转基因小鼠模型。

主要发现

  • 两种改变强烈协同诱导细胞遗传学正常的AML,但未增加自我更新潜能。
  • 分子水平上Htra3强烈上调、Lin28a下调,导致增殖增强并抑制凋亡和分化。
  • 在FLT3-ITD存在下,Htra3过表达与Lin28a敲低共现诱导的AML形态与双转基因小鼠白血病细胞相似。
  • 这些白血病细胞对蛋白酶体抑制剂卡非佐米高度敏感。
  • 卡非佐米强烈增强靶向AXL(FLT3上游)对小鼠和人白血病细胞的活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With an incidence of ~50%, the absence or reduced protein level of p53 is much more common than TP53 mutations in acute myeloid leukemia (AML). AML with FLT3-ITD (internal tandem duplication) mutations has an unfavorable prognosis and is highly associated with wt-p53 dysfunction. While TP53 mutation in the presence of FLT3-ITD does not induce AML in mice, it is not clear whether p53 haploinsufficiency or loss cooperates with FLT3-ITD in the induction of AML. Here, we generated FLT3-ITD knock-in; p53 knockout (heterozygous and homozygous) double-transgenic mice and found that both alterations strongly cooperated in the induction of cytogenetically normal AML without increasing the self-renewal potential. At the molecular level, we found the strong upregulation of Htra3 and the downregulation of Lin28a, leading to enhanced proliferation and the inhibition of apoptosis and differentiation. The co-occurrence of Htra3 overexpression and Lin28a knockdown, in the presence of FLT3-ITD, induced AML with similar morphology as leukemic cells from double-transgenic mice. These leukemic cells were highly sensitive to the proteasome inhibitor carfilzomib. Carfilzomib strongly enhanced the activity of targeting AXL (upstream of FLT3) against murine and human leukemic cells. Our results unravel a unique role of p53 haploinsufficiency or loss in the development of FLT3-ITD + AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yang M, Pan Z, Huang K, et al. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. Leukemia. 2021. PMID: 34732858. doi:10.1038/s41375-021-01452-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。